FindTrial
Sign In

Eye Study: How Anti-VEGF Injections Affect Eye Nerves and Blood Flow, and Whether Brimonidine Drops Help

To Analyse Acute Peripapillary Angiographic and Retinal Nerve Fibre Layer changes following intravitreal anti-VEGF injections: a case-control study with and without use of Brimonidine eye drops. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/093952
Enrollment
220
Registered
2025-09-01
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H350- Background retinopathy and retinalvascular changes Health Condition 2: H353- Degeneration of macula and posterior pole Health Condition 3: H349- Unspecified retinal vascular occlusion

Interventions

Intervention1: BRIMONIDINE 0.15 PERCENT EYE DROP: CASES WILL RECEIVE SINGLE DROP OF BRIMINIDINE 0.15 PERCENT EYE DROP 30 MINUTES BEFORE INJECTION Control Intervention1: NA: NA

Sponsors

SANKARA EYE HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1)PATIENTS INDICATED FOR INTRAVITREAL ANTI-VEGF INJECTION (EG-DIABETIC MACULAR EDEMA, AGE-RELATED MACULAR DEGENERATION, RETINAL VEIN OCCLUSIONS) 2)BEST CORRECTED VISUAL ACUITY MORE THAN 6/60 3)AGE GREATER THAN 18 YEARS 4)CLEAR MEDIA 5)PHAKIC OR PSEUDOPHAKIC EYES 6)GOOD FIXATION ABILITY 7)INTRAOCULAR PRESSURE LESS THAN 21 MMHG BEFORE INJECTION 8)CONSENT TO PARTICIPATE IN THE STUDY

Exclusion criteria

Exclusion criteria: 1)KNOWN ALLERGY TO BRIMONIDINE 0.15 PERCENT EYE DROP 2)USE OF ANY INTRAOCULAR PRESSURE LOWERING EYE DROPS WITHIN THE PAST 2 WEEKS. 3)HISTORY OF UVEITIS OR OCULAR INFLAMMATION 4)PREVIOUS VITRECTOMY OR GLAUCOMA SURGERY IN THE STUDY EYE 5)KNOWN CASE OF GLAUCOMA 6)MEDIA OPACITIES (DENSE CATARACT, CORNEAL OPACITY, VITREOUS HAEMORRHAGE) 7)POOR OCT, OCT-A IMAGE QUALITY 8)HIGH MYOPIA (MORE THAN -6.00 D SPHERICAL EQUIVALENT OR AXIAL LENTH MORE THAN 26.5MM) 9)CONCURRENT RETINAL PATHOLOGIES LIKE RETINAL DETACHMENT, MACULAR HOLE 10)APHAKIC EYES 11)PATIENTS UNDERGOING TREATMENT WITH AFLIBERCEPT 0.1ML

Design outcomes

Primary

MeasureTime frame
CHANGE IN PERIPAPILLARY RETINAL NERVE FIBRE LAYER THICKNESS AND PRIPAPILLARY VASCULAR PERFUSION DENSITYTimepoint: 30 MINUTES BEFORE AND AFTER THE INTRAVITREAL ANTI-VEGF INJECTION.—

Secondary

MeasureTime frame
CHANGE IN INTRAOCULAR PRESSURETimepoint: BEFORE AND 5 MINUTES AFTER INTRAVITREAL ANTIVEGF INJECTION;CORRELATION BETWEEN INTRAOCULAR PRESSURE AND PERIPAPILLARY RETINAL NERVE FIBRE LAYER AND VASCULAR CHANGES(VESSEL DENSITY, PERFUSION DENSITY)Timepoint: ;SAFETY AND FEASIBILITY OF BRIMONIDINE USETimepoint:—

Countries

India

Contacts

Public ContactPAVITHRA R V

SANKARA EYE HOSPITAL

minija_ck@yahoo.co.in9480587018

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026